Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of $0.25, $0.65 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $108.8 million versus the consensus estimate of $20.2 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.